-
1.发明授权Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 有权针对程序性死亡1的人单克隆抗体（PD-1）以及单独或与其他免疫治疗剂组合使用抗PD-1抗体治疗癌症的方法
公开(公告)号：EP2161336B1
公开(公告)日：2013-07-31
申请号：EP09013687.0
申请日：2006-05-02
发明人： Korman, Alan, J. , Srinivasan, Mohan , Wang, Changyu , Selby, Mark. J. , Chen, Bing , Cardarelli, Josephine M. , Huang, Haichun
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
公开(公告)号：EP2439273A3
公开(公告)日：2012-10-03
申请号：EP11178191.0
申请日：2006-05-02
发明人： Srinivasan, Mohan , Wang, Changyu , Selby, Mark J. , Chen, Bing , Cardarelli, Josephine M. , Korman, Alan J.
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/464 , Y02A50/466 , Y02A50/467 , Y02A50/469 , Y02A50/478 , Y02A50/487 , Y02A50/489
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
3.发明公开Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 审中-公开为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2439273A2
公开(公告)日：2012-04-11
申请号：EP11178191.0
申请日：2006-05-02
发明人： Srinivasan, Mohan , Wang, Changyu , Selby, Mark J. , Chen, Bing , Cardarelli, Josephine M. , Korman, Alan J.
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/414 , Y02A50/464 , Y02A50/466 , Y02A50/467 , Y02A50/469 , Y02A50/478 , Y02A50/487 , Y02A50/489
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
摘要翻译： 本发明提供了分离的单克隆抗体，特别是人单克隆抗体，并特异性结合PD-1以高亲和力。 编码本发明的抗体的核酸分子，表达载体，宿主细胞和表达本发明的抗体的方法因此提供。 因此免疫缀合物，双特异性分子和药物组合物包含本发明的抗体提供的。 因此，本发明提供了用于治疗各种疾病，包括癌症和感染性疾病，使用抗PD-1抗体用于检测PD-1的方法，以及方法。 本发明进一步提供了使用免疫疗法组合,:方法如抗CTLA-4和抗PD-1抗体的组合，以治疗过度增殖性疾病，：如癌症。 因此本发明提供用于改变与治疗相关的独立与测试的抗体的不良事件的方法。
-
4.发明公开Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 有权为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2161336A1
公开(公告)日：2010-03-10
申请号：EP09013687.0
申请日：2006-05-02
发明人： Korman, Alan, J. , Srinivasan, Mohan , Wang, Changyu , Selby, Mark. J. , Chen, Bing , Cardarelli, Josephine M.
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
5.发明授权Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics 有权为程序性死亡-1（PD-1）的人单克隆抗体，并用单独PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
公开(公告)号：EP2161336B2
公开(公告)日：2017-03-29
申请号：EP09013687.0
申请日：2006-05-02
发明人： Korman, Alan, J. , Srinivasan, Mohan , Wang, Changyu , Selby, Mark. J. , Chen, Bing , Cardarelli, Josephine M. , Huang, Haichun
CPC分类号： A61K39/39558 , A61K39/00 , A61K39/3955 , A61K47/6849 , A61K51/10 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
-
6.发明公开Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) 审中-公开HumanisierteAntikörpergegen干扰素-α-受体激动剂-1（IFNAR-1）
公开(公告)号：EP2404615A1
公开(公告)日：2012-01-11
申请号：EP10011473.5
申请日：2004-04-23
申请人： Medarex, Inc.
发明人： Cardarelli, Josephine M. , Chen, Tseng-hui, Timothy , King, David , Bebbinbton, Christopher R. , Pogue, Sarah Lee , Carr, Francis J. , Williams, Stephen
IPC分类号： A61K39/395 , C07K16/24 , C07K16/46 , C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/70 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
摘要翻译： 公开了结合IFNAR-1的人源化单克隆抗体以及相关的基于抗体的组合物和分子。 还公开了包含人源化抗体和使用人源化抗体的治疗和诊断方法的药物组合物。
-
公开(公告)号：EP2486941A1
公开(公告)日：2012-08-15
申请号：EP12155398.6
申请日：2007-10-01
申请人： Medarex, Inc.
IPC分类号： A61K39/395 , C07K16/28 , A61K47/48
CPC分类号： C07K16/2866 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.024 秒)
